Stockscreener 앱 받기
16.33
1.62%
0.26
시간 외 거래:
16.26
-0.07
-0.43%
전일 마감가:
$16.07
열려 있는:
$16.05
하루 거래량:
12.85M
Relative Volume:
1.24
시가총액:
$19.02B
수익:
$14.57B
순이익/손실:
$-296.50M
주가수익비율:
-63.05
EPS:
-0.259
순현금흐름:
$1.64B
1주 성능:
+6.25%
1개월 성능:
+0.43%
6개월 성능:
+32.55%
1년 성능:
+79.06%
1일 변동 폭
$16.02
$16.43
1주일 범위
$15.07
$16.43
52주 변동 폭
$8.625
$17.53
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.33 | 18.71B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 49.45B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 40.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 39.15B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.09 | 32.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
542.66 | 23.07B | 3.17B | 1.29B | 1.01B | 27.09 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com Canada
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com Canada
Planned sale: Viatris (VTRS) officer disposes 50,076 shares - Stock Titan
Price to sales forward of Viatris Inc. – NASDAQ:VTRS - TradingView
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris, Inc. Actuals & Estimates (SWB:VIA) - TradingView
Form 144 Viatris Inc For: 25 June By Investing.com - Investing.com Canada
Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries - Stock Titan
How Viatris’ €650 Million Eurobond Issue (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo! Finance Canada
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Investor Outlook: Is The 15.89% Potential Upside Worth The Risk? - DirectorsTalk Interviews
Come As You Are: Emily Smith Builds Solidarity, Support for LGBTQ+ Colleagues Through VIVID - CSRwire
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 Debt - TradingView
Viatris (NASDAQ: VTRS) issues €650M 4.25% notes to help refinance 2026 debt - Stock Titan
(VTRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
XS332542958 Bond Price and Chart — FWB:XS332542958 - TradingView
Viatris Inc (VTRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viatris Inc (VTRS) Institutional Confidence - TradingKey
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris Recognized as One of the 2026 Best Workplaces™ in Canada - Yahoo Finance
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Viatris (VTRS) sells €650M 4.25% senior notes to refinance 2026 debt - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan
A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews
Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com
Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria
Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Salesforce Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - Salesforce
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
0.13%
자본화:
|
볼륨(24시간):